Drug Trial Radar · NCT07070518
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Last checked: Nov 20, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Jul 11, 2025
Primary completion
Jul 16, 2027
Study completion Sep 16, 2028
Sponsor
- Lead sponsor
- GV20 TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Conditions
- Solid Tumor Cancer
- Adult Refractory Cancer
- Endometrial Carcinoma (EC)
- Squamous Head and Neck Carcinoma
- pMMR/MSS Adenocarcinoma of the Colon or Rectum
- Non-Small Cell Lung Cancer
- Melanoma
- HCC - Hepatocellular Carcinoma
- Small Cell Lung Cancer
Interventions
GV20-0251Drug
Part A: Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks Part B: GV20-0251 preliminary RP2D administered by IV infusion once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate anti-tumor activities with GV20-0251Time frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until disease progression or end of study (whichever occurs first, up to 24 months)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.